Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 16/20 | 0.80 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.64 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6392181 | 1.00 | PTGS2 (0.80) | PTGS2GABRA2GABRB2PTGS1 | |
| SCHEMBL6389713 | 0.90 | PTGS2 (0.66) | PTGS2GABRA2GABRB2PTGS1 | |
| SCHEMBL6391363 | 0.90 | PTGS2 (0.66) | PTGS2GABRA2GABRB2PTGS1 | |
| SCHEMBL5594811 | 0.89 | PTGS2 (1.00) | PTGS2GABRA2GABRB2PTGS1 | |
| SCHEMBL5594360 | 0.87 | PTGS2 (0.74) | PTGS2GABRA2GABRB2PTGS1 | |
| SCHEMBL5593914 | 0.87 | PTGS2 (0.74) | PTGS2GABRA2GABRB2PTGS1 | |
| SCHEMBL6390052 | 0.87 | PTGS2 (0.74) | PTGS2GABRA2GABRB2PTGS1 | |
| SCHEMBL5594222 | 0.86 | PTGS2 (0.70) | PTGS2GABRA2GABRB2PTGS1 | |
| SCHEMBL6391197 | 0.86 | PTGS2 (0.70) | PTGS2GABRA2GABRB2PTGS1 | |
| SCHEMBL6393310 | 0.86 | PTGS2 (0.72) | PTGS2GABRA2GABRB2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220770-B2 | Heterocyclo-substituted imidazoles for the treatment of inflammation | KHANNA ISH K | 2007-05-22 | — | — | US | disclosed |
| US-20050256120-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | KHANNA ISH K | 2005-11-17 | — | — | US | disclosed |
| US-20050096368-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | G.D. SEARLE & CO. | 2005-05-05 | — | — | US | disclosed |
| US-5616601-A | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation | GD SEARLE & CO (US) | 1997-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256120-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | LTC4S, HRH4, LTB4R2 | PTGS2 107/4885GABRA2 1727/4885GABRB2 1850/4885 |
| US-20050096368-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | HRH4, LTC4S, HCAR3 | PTGS2 150/4885GABRA2 1821/4885GABRB2 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.